


11-29-01

1644 RECEIVED



REFERENCE CITED BY APPLICANT
(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.
03528-0300US00

APPLICATION NO.
09/426,205

APPLICANT
Little, et al.

FILING DATE
06/02/00

GROUP
1644

DEC 03 2001
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1.						

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
JMR	1.	WO 94/28027	12/08/94	PCT	5			
JMR	2.	WO 94/29350	12/22/94	PCT	5			
	3.							

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

JMR	1.	Adair et al., "Humanization of the murine anti-human CD3 monoclonal antibody OKT3" Human. Antibod. Hybridomas, Vol. 5, pp. 41-47 (1994)
	2.	Dubel et al., "Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers" <i>J. Immunol. Methods</i> <u>175</u> , pp. 89-95 (1994)
	3.	Götter et al., "A single-chain antibody for coupling ligands to tumor cells infected with Newcastle disease virus" <i>Tumor Targeting</i> <u>1</u> , pp. 107-114 (1995)
	4.	Kipriyanov et al., "Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry" <i>J. Immunol. Methods</i> <u>196</u> pp. 51-62 (1996)
	5.	Kipriyanov et al., "Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion by not the affinity" <i>Protein Engineering</i> , Vol. 10(4) April 1997, p. 445-453.
	6.	Daniel J. Kroon et al. "Identification of Sites of Degradation in a Therapeutic Monoclonal Antibody by Peptide Mapping" <i>Pharmaceutical Research</i> Vol. 9(11) November 1992 p. 1386-1393.
	7.	Kung et al., "Monoclonal Antibodies Defining Distinctive Human T Cell Surface Antigens" <i>Science</i> <u>206</u> , pp. 347-349 (1979)
JMR	8.	Kungel et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection" <i>Meth. Enzymol.</i> <u>154</u> , pp. 367-382 (1987)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


JMR 3/10/02

RECEIVED

DEC 03 2001

TECH CENTER 1600/2900

REFERENCE CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 03528-00 00US00	APPLICATION NO. 09/424,788
	APPLICANT Little, et al.	
	FILING DATE 06/02/00	GROUP 1644



9.	Nitta et al., "Preliminary trial of specific targeting therapy against malignant glioma" <i>Lancet</i> <u>335</u> , pp. 368-376 (1990)
10.	Sanna et al., "Rapid Assay of Phage-Derived Recombinant Human Fabs as Bispecific Antibodies" <i>Bio/Technology</i> <u>13</u> , pp. 1221-1224 (1995)
11.	Thistlethwaite et al. "Evolving use of OKT3 Monoclonal Antibody for Treatment of Renal Allograft Rejection" <i>Transplantation</i> <u>38</u> , pp. 695-701 (1984)
12.	Transy et al., "Most anti-human CD3 monoclonal antibodies are directed to the CD3 subunit" <i>Eur. J. Immunol.</i> <u>19</u> , pp. 947-950 (1989)
13.	Wan Wauwe et al., "A Monoclonal Anti-Human T Lymphocyte Antibody with Potent Mitogenic Properties" <i>J. Immunol.</i> <u>124</u> , pp. 2708-2713 (1980)
14.	Woodle et al. "Humanized OKT3 antibodies: Successful Transfer of Immune Modulating Properties and Idiotypic Express" <i>J. Immunol.</i> <u>148</u> , pp. 2756-2763 (1992)
15.	Woodle et al. "OKT3 Therapy for Hepatic Allograft Rejection" <i>Transplantation</i> <u>51</u> , pp. 1207-1212 (1991)
16.	Yannelly et al., "Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy" <i>J. Immunol. Meth.</i> <u>1</u> , pp. 91-100 (1990)

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[Signature] 3/10/02